Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Nov 11, 2010

Premium

Alnylam Pharmaceuticals said that it has expanded its management team to include two new vice presidents and a CSO.

Kenneth Koblan, who has been named CSO, previously held various positions within Merck Research Laboratories, most recently vice president and site head of Rahway Basic Research. He holds a PhD in biochemistry from Johns Hopkins University.

Alnylam's previous CSO, John Schmidt, left the company in August of 2009.

The company also said that it has appointed Steven Bossone as its vice president of intellectual property and Garvin Warner as its vice president of preclinical development.

Bossone previously served as senior patent attorney at Shire, and had worked as a scientist in the oncology group of Millennium Pharmaceuticals. Warner previously served as assistant vice president and therapeutic area head in drug safety and metabolism at Genetics Institute/Wyeth.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.